LegoChem Biosciences Inc - Asset Resilience Ratio
LegoChem Biosciences Inc (141080) has an Asset Resilience Ratio of 56.48% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read LegoChem Biosciences Inc total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2024)
This chart shows how LegoChem Biosciences Inc's Asset Resilience Ratio has changed over time. See LegoChem Biosciences Inc (141080) net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down LegoChem Biosciences Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 141080 market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩395.06 Billion | 56.48% |
| Total Liquid Assets | ₩395.06 Billion | 56.48% |
Asset Resilience Insights
- Very High Liquidity: LegoChem Biosciences Inc maintains exceptional liquid asset reserves at 56.48% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
LegoChem Biosciences Inc Industry Peers by Asset Resilience Ratio
Compare LegoChem Biosciences Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for LegoChem Biosciences Inc (2014–2024)
The table below shows the annual Asset Resilience Ratio data for LegoChem Biosciences Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 49.44% | ₩365.04 Billion ≈ $247.38 Million |
₩738.38 Billion ≈ $500.39 Million |
+21.79pp |
| 2023-12-31 | 27.65% | ₩52.40 Billion ≈ $35.51 Million |
₩189.50 Billion ≈ $128.42 Million |
+2.95pp |
| 2022-12-31 | 24.71% | ₩62.39 Billion ≈ $42.28 Million |
₩252.53 Billion ≈ $171.14 Million |
+4.11pp |
| 2021-12-31 | 20.60% | ₩60.39 Billion ≈ $40.93 Million |
₩293.23 Billion ≈ $198.72 Million |
-17.10pp |
| 2020-12-31 | 37.70% | ₩51.24 Billion ≈ $34.72 Million |
₩135.91 Billion ≈ $92.11 Million |
+4.45pp |
| 2019-12-31 | 33.25% | ₩47.03 Billion ≈ $31.87 Million |
₩141.48 Billion ≈ $95.88 Million |
-18.23pp |
| 2018-12-31 | 51.48% | ₩62.64 Billion ≈ $42.45 Million |
₩121.69 Billion ≈ $82.47 Million |
+25.31pp |
| 2017-12-31 | 26.17% | ₩21.52 Billion ≈ $14.58 Million |
₩82.24 Billion ≈ $55.73 Million |
-9.70pp |
| 2016-12-31 | 35.87% | ₩32.12 Billion ≈ $21.77 Million |
₩89.55 Billion ≈ $60.69 Million |
+11.53pp |
| 2015-12-31 | 24.34% | ₩16.66 Billion ≈ $11.29 Million |
₩68.44 Billion ≈ $46.38 Million |
-59.82pp |
| 2014-12-31 | 84.16% | ₩28.41 Billion ≈ $19.25 Million |
₩33.76 Billion ≈ $22.88 Million |
-- |
About LegoChem Biosciences Inc
LigaChem Biosciences Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of medicines for unmet medical needs. The company researches and develops products for various therapeutic areas, including antibiotics, anti-fibrotics, immuno-oncology, oncology; and antibody-drug conjugate (ADC) platform technology and small molecule drugs. It also sells medical devic… Read more